Maria Sainz was appointed President and CEO of AEGEA Medical in May 2018. She has over 25 years’ experience in commercial and leadership positions in the medtech industry. Maria has served as the President and CEO of Cardiokinetix, a medical device company pioneering a catheter-based treatment for heart failure. Prior to that, Maria was the President and CEO of Concentric Medical, Inc., a developer of minimally invasive products for the treatment of acute ischemic stroke which was acquired in 2011 by Stryker Corporation. Maria began her medtech career at Guidant Corporation where she held positions of increasing responsibility in Europe and the US. At the time of the acquisition of Guidant by Boston Scientific, Maria served as President of the Cardiac Surgery division of Guidant Corporation. Maria has been intimately involved in several major medtech product launches such as coronary stents or cardiac resynchronization therapy devices. Maria also serves as a director of several public and private medical company boards. She received an M.A in Languages from the University Complutense in Madrid, Spain and a Masters in International Management from the American Graduate School of International Management.
An active and powerful board of experienced professionals drives us to our greatest level of success.
Maria Sainz was appointed President and CEO of AEGEA Medical in May 2018. She has over 25 years’ experience in commercial and leadership positions in … Read more
Maria Sainz - President & CEO
Dave has worked with the partners of Solas BioVentures Fund since 2004 and was a founding member of the fund in 2014. Dave is a … Read more
David Adair MD - Chairman of the Board, Co-Founder & Managing Director – Solas BioVentures
Dave has worked with the partners of Solas BioVentures Fund since 2004 and was a founding member of the fund in 2014. Dave is a long-time physician, educator, administrator, innovator, and biotech/med-tech investor with nearly 20 years of experience in angel and venture investing. Dave recently retired as Professor and Vice Chairman of the Department of Obstetrics and Gynecology at the University of Tennessee College of Medicine. Dave is Board certified in Maternal-Fetal Medicine, Obstetrics and Gynecology, and Hypertension, with special expertise in Critical Care. Dave received a BS in Biology from Morehead State University, where he is Hall of Fame member, and is a graduate from The University Tennessee Chattanooga with a Master of Business Administration with a concentration in Healthcare. Dave earned his medical degree from the Joan C. Edwards College of Medicine at Marshall University and completed residency at the University of Florida Health Science Center and Fellowship training at Wake Forest University.
Besides serving as the Chairman of the board at Aegea Medical, Dave serves as a director Biostable SE, Arrivo Bio Ventures, Advanced Catheter Therapies, PreTel Health, Velo Bio, and Anogen Life Sciences. Dave and his colleagues have invested in many cutting edge and disruptive medical device and biotech companies, including Veran Medical Technologies (where he served previously as a board director), Addrenex, acquired by Sciele/Shionogi (OTCMKTS:SGIOY); Neuronex, acquired by Acorda (NASDAQ:ACOR); Velo Bio, acquired by AMAG Pharmaceuticals (NASDAQ:AMAG); Aerial Bio, acquired by Jazz Pharmaceuticals (NASDAQ:JAZZ); and NxThera, acquired by Boston Scientific (NYSE:BSX). Dave also founded Glenveigh Medical, which had a therapeutic out-licensed to Protherics (FTSE:PTIL) and medical devices acquired by Clinical Innovations.
Josh has spent over 25 years in the healthcare industry working across a broad range of responsibilities and companies ranging from early stage product development … Read more
Josh Baltzell - Director – Sightline Partners
Josh has spent over 25 years in the healthcare industry working across a broad range of responsibilities and companies ranging from early stage product development and innovation all the way up to public offerings and mergers and acquisitions for mature companies.
Josh currently serves as a Venture Partner at SightLine partners where he focuses on sourcing and managing investments in the health care industry. Prior to SightLine, Josh was a Managing Director at Split Rock Partners. A lead investor and board member in companies with an aggregate, realized value of over $2 billion, some of his notable past successes as a venture investor include Ardian – acquired by Medtronic for ~$800M, Entellus Medical – acquired by Stryker for ~$700M, RF Surgical – acquired by Medtronic for $235M and SkinMedica – acquired by Allergan for $350M.
In addition to Aegea, Josh currently serves as a board director at Colorescience, Koya Medical, Magnolia Medical, and ViewPoint Medical and also serves as an advisor to TMRW.
Josh earned Bachelor degrees in Economics and Philosophy from St. Olaf College and an M.B.A. from The Carlson School at the University of Minnesota.
Important Safety Information:
The Mara Water Vapor Ablation System is indicated to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia due to benign causes for whom childbearing is complete. Pregnancy following the Mara procedure can be dangerous. The Mara procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. As with all surgical procedures, there are risks and considerations associated with the use of the Mara Water Vapor Ablation System. Please refer to the device labeling for a detailed discussion of the device’s intended use, relevant warnings, precautions, side effects, and contraindications.